| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-111SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-78444SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-33130 | |||
| IHC-Prediluted | NBP2-45339 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-47518SS | |||
| Azide and BSA Free | NBP2-80610 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-46892SS | |||
| Azide and BSA Free | NBP2-80829 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB400-128SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-50037SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-27416 | |||
| BSA Free | NB100-56712SS | |||
| Azide and BSA Free | NBP2-27416SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-50028SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56112SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-91810-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-24915SS | |||
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo and synergizes with ionizing radiation to inhibit tumor growth( Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). Sections of PSN1 xenografts and in-vitro PSN1 cells fixed and stained with anti-NPM (red) and anti-p14ARF (green). Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested in HeLa cells with Dylight 488 (green). Nuclei were counterstained with DAPI (blue). Tubulin was stained with alpha tubulin (red).](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - ARF expression levels in OCI/AML3 cells after proteasome treatment. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0009.jpg)
![Flow Cytometry: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested at 1:400 in HeLa cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Flow-Cytometry-NB200-111-img0007.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Analysis of HeLa Whole Cell Lysate (NB800-PC1) using p14ARF antibody (lot C) employing ECL detection method.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0008.jpg)
![Immunohistochemistry-Frozen: p14ARF/CDKN2A Antibody [NB200-111] - Mouse brain section, hippocampal (10 um thickness). 3% PFA perfused. 1:1000 dilultion. Image from verified customer review. Image using the Biotin form of this antibody.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-Frozen-NB200-111-img0010.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203719.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212372.jpg)
![Immunocytochemistry/ Immunofluorescence: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo & synergizes with ionizing radiation to inhibit tumor growth(A) PSN1 xenografts (PSN1 cells co-injected with LTC-14 stellate cells) established in the flank of athymic nude mice were treated with MK-2206 (60 mg/kg-320 mg/kg) as indicated or beta -cyclo-dextrin (1.5 mg/ml) carrier. Xenograft tumors were lysed & lysates probed by western blot with the indicated antibodies. (B-D) Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). (B) Sections of PSN1 xenografts & in-vitro PSN1 cells fixed & stained with anti-NPM (red) & anti-p14ARF (green). (C) PSN1 xenografts treated with MK-2206 or carrier were stained with DAPI, anti-p53 (DO1) or p53mut (OP29 clone) (D) PSN1 xenografts treated with MK-2206 (60 mg/kg) or carrier were stained by immunohistochemical methods with anti-pS473-AKT, anti-phospho-S48-NPM (pS48-NPM) or p53. (E) PSN1 xenografts established in the flank of athymic nude mice were injected subcutaneously with two alternate day doses of MK-2206 (60 mg/kg) or carrier. Mice were subsequently treated with a single dose of IR (6 Gy) & tumor volumes measured regularly with callipers. Dash lines indicate tumor growth differential at 250 mm3. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203724.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205197.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212370.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205120.jpg)
![Western Blot: Mas Antibody [NBP1-78444] - Analysis of MAS1 in: (1) Ntera 2, (2) A431, (3) HepG2, (4) MCF7, (5) 3T3, and (6) Cos7.](http://images.novusbio.com/fullsize/Mas-Antibody-Western-Blot-NBP1-78444-img0008.jpg "Western Blot: Mas Antibody [NBP1-78444] - Analysis of MAS1 in: (1) Ntera 2, (2) A431, (3) HepG2, (4) MCF7, (5) 3T3, and (6) Cos7.")
![Immunocytochemistry/Immunofluorescence: Mas Antibody [NBP1-78444] - Tested at 1:25 in HepG2 cells with FITC (green). Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/Mas-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-78444-img0006.jpg)
![Immunohistochemistry: Mas Antibody [NBP1-78444] - Analysis of MAS1 in mouse kidney using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/Mas-Antibody-Immunohistochemistry-NBP1-78444-img0007.jpg)
![Simple Western: Mas Antibody [NBP1-78444] - Lane view shows a specific band for MAS1 in 0.5 mg/ml of HepG2 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Mas-Antibody-Simple-Western-NBP1-78444-img0009.jpg)
![Western Blot: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Western Blot Analysis of human brain tissue lysate using UCH-L1/PGP9.5 Antibody (31A3)](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Western-Blot-NB600-1160-img0013.jpg "Western Blot: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Western Blot Analysis of human brain tissue lysate using UCH-L1/PGP9.5 Antibody (31A3)")
![Immunocytochemistry/Immunofluorescence: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Immunofluorescence Analysis of T98G cells labeling Pgp9.5 with UCH-L1/PGP9.5 Antibody (31A3) followed by Goat anti-Mouse IgG-CF488 (Green). The nuclear counterstain is Nucspot (Red)](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Immunocytochemistry-Immunofluorescence-NB600-1160-img0012.jpg)
![Immunohistochemistry-Paraffin: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Formalin-fixed, paraffin-embedded human brain stained with UchL1 antibody (PGP9.5) (1:500), peroxidase-conjugate and DAB chromogen. Staining seen in cytoplasm, ER and membrane. Fixation in 95% ethanol/5% acetic acid for 2-3 hours prior to paraffin embedding is recommended. Specimens which have not been fixed in acetic acid/alcohol require pre-treatment with citrate buffer: for example, unmask of the target epitope by boiling the tissue sections in 10mM citrate buffer, pH 6.0, for 10 min followed by cooling at room temp for 20 min.](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Immunohistochemistry-Paraffin-NB600-1160-img0004.jpg)
![Flow Cytometry: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Flow Cytometric Analysis of T98G cells using UCH-L1/PGP9.5 Antibody (31A3)followed by Goat anti-Mouse IgG-CF488 (Blue); Isotype Control (Red).](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Flow-Cytometry-NB600-1160-img0011.jpg)
![Western Blot: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - analysis of UchL1 in 1) human, 2) mouse and 3) rat brain lysate using UchL1 antibody at 1 ug/ml. goat anti-mouse Ig HRP secondary antibody and ECL substrate solution were used for this test.](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Western-Blot-NB600-1160-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - analysis of PGP9.5 in rat mesenteric artery using anti-PGP9.5 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Immunocytochemistry-Immunofluorescence-NB600-1160-img0005.jpg)
![Simple Western: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Simple Western lane view shows a specific band for PGP9.5 / UCHL-1 in 0.2 mg/ml of h. Cerebellum (left) and IMR-32 (right) lysate(s). This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Simple-Western-NB600-1160-img0006.jpg)
![Simple Western: UCH-L1/PGP9.5 Antibody (31A3) [NB600-1160] - Electropherogram images of the corresponding Simple Western lane. PGP9.5 / UCHL-1 antibody was used at 10 ug/ml dilution of h. Cerebellum and IMR-32 lysates(s) respectively.](http://images.novusbio.com/fullsize/UCH-L1-PGP9-5-Antibody-31A3-Simple-Western-NB600-1160-img0010.jpg)
![Western Blot: Calreticulin Antibody (1G6A7) [NBP1-47518] - Analysis of whole cell lysates from HeLa, A549, NTERA2 and MCF-7 using Calreticulin antibody clone 1G6A7. The antibody generated a specific band of Calreticulin protein at ~48 kDa molecular weight position.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Western-Blot-NBP1-47518-img0017.jpg "Western Blot: Calreticulin Antibody (1G6A7) [NBP1-47518] - Analysis of whole cell lysates from HeLa, A549, NTERA2 and MCF-7 using Calreticulin antibody clone 1G6A7. The antibody generated a specific band of Calreticulin protein at ~48 kDa molecular weight position.")
![Flow (Intracellular): Calreticulin Antibody (1G6A7) [NBP1-47518] - Intracellular staining of 1 x 10^6 CHO (A) and HEK-293 (B) cells using Calreticulin antibody (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1x10^6 cells was used.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Flow-Cytometry-NBP1-47518-img0016.jpg)
![Immunocytochemistry/Immunofluorescence: Calreticulin Antibody (1G6A7) [NBP1-47518] - Antibody was tested in HeLa cells at a 1:250 against DyLight 488 (Green). Actin was counterstained against Phalloidin 568 (Red) and cells were mounted in DAPI Flouromount (Blue).](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Immunocytochemistry-Immunofluorescence-NBP1-47518-img0008.jpg)
![Western Blot: Calreticulin Antibody (1G6A7) [NBP1-47518] - Analysis using Calreticulin mouse mAb against HEK293T cells transfected with the pCMV6-ENTRY control (1) and pCMV6-ENTRY Calreticulin cDNA (2).](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Western-Blot-NBP1-47518-img0005.jpg)
![Immunohistochemistry-Paraffin: Calreticulin Antibody (1G6A7) [NBP1-47518] - Analysis of paraffin-embedded human placenta tissues using anti-Calreticulin mAb.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Immunohistochemistry-Paraffin-NBP1-47518-img0002.jpg)
![Flow Cytometry: Calreticulin Antibody (1G6A7) [NBP1-47518] - An intracellular stain was performed on A431 cells with Calreticulin (1G6A7) Antibody NBP1-47518 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 488.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Flow-Cytometry-NBP1-47518-img0038.jpg)
![Immunocytochemistry/Immunofluorescence: Calreticulin Antibody (1G6A7) [NBP1-47518] - Analysis of 3T3-L1 cells using anti-Calreticulin mAb (green). DRAQ5 fluorescent DNA dye (blue).](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Immunocytochemistry-Immunofluorescence-NBP1-47518-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: Calreticulin Antibody (1G6A7) [NBP1-47518] - Analysis of SKBR-3 (left) and A549 (right) cells using anti-Calreticulin mAb (green). Actin filaments have been labeled with DY-554 phalloidin (red). DRAQ5 fluorescent DNA dye (blue).](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Immunocytochemistry-Immunofluorescence-NBP1-47518-img0007.jpg)
![Flow (Intracellular): Calreticulin Antibody (1G6A7) [NBP1-47518] - A549 cells stained with NBP1-47518PCP (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to PerCP.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Flow-Cytometry-NBP1-47518-img0026.jpg)
![Flow (Intracellular): Calreticulin Antibody (1G6A7) [NBP1-47518] - U-937 cells stained with NBP1-47518F (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to FITC.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Flow-Cytometry-NBP1-47518-img0027.jpg)
![Flow (Intracellular): Calreticulin Antibody (1G6A7) [NBP1-47518] - Jurkat cells stained with NBP1-47518APC (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to allophycocyanin.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Flow-Cytometry-NBP1-47518-img0028.jpg)
![Flow Cytometry: Calreticulin Antibody (1G6A7) [NBP1-47518] - An intracellular stain was performed on HeLa cells with Calreticulin Antibody [1G6A7] NBP1-47518AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/Calreticulin-Antibody-1G6A7-Flow-Cytometry-NBP1-47518-img0034.jpg)
![Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Western Blot analysis shows lysates of HeLa human cervical epithelial carcinoma parental cell line and LC3B knockout HeLa cell line (KO) untreated (-) or treated (+) with 50 uM Chloroquine for 18 hours. PVDF (Polyvinylidene difluoride) membrane was probed with 2.0 ug/mL of Rabbit Anti-Human/Mouse/Rat LC3B Monoclonal Antibody (1251A) [Catalog # NBP2-46892] followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog# HAF008). A specific band was detected for LC3B at a molecular weight of approximately 15 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. GAPDH is shown as a loading control. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Knockout-Validated-NBP2-46892-img0028.jpg "<b>Genetic Strategies Validation. </b>Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Western Blot analysis shows lysates of HeLa human cervical epithelial carcinoma parental cell line and LC3B knockout HeLa cell line (KO) untreated (-) or treated (+) with 50 uM Chloroquine for 18 hours. PVDF (Polyvinylidene difluoride) membrane was probed with 2.0 ug/mL of Rabbit Anti-Human/Mouse/Rat LC3B Monoclonal Antibody (1251A) [Catalog # NBP2-46892] followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog# HAF008). A specific band was detected for LC3B at a molecular weight of approximately 15 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. GAPDH is shown as a loading control. This experiment was conducted under reducing conditions.")
![<b>Genetic Strategies Validation. </b>Immunocytochemistry/ Immunofluorescence: LC3B Antibody (1251A) [NBP2-46892] - LC3B was detected in immersion fixed Chloroquine treated Hela cells (left) but was not detected in LC3B knockout Hela cells (right) using rabbit anti-human LC3B monoclonal antibody (1251A) [Catalog #NBP2-46892] at 0.3 ug/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Rabbit IgG Secondary Antibody (red; Catalog # NL004) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Knockout-Validated-NBP2-46892-img0036.jpg)
![Western Blot: LC3B Antibody (1251A) [NBP2-46892] - The expression of LC3B in rat tissue. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Western-Blot-NBP2-46892-img0034.jpg)
![<b>Biological Strategies Validation. </b>Flow (Intracellular): LC3B Antibody (1251A) [NBP2-46892] - Jurkat cells were either untreated (A) or treated with 50uM chloroquine for 24 hours (B). An intracellular stain was performed with anti-LC3B (1251A) antibody [Catalog # NBP2-46892] (blue) and a matched isotype control [Catalog # MAB1050] (orange). Cells were fixed with 4% paraformaldehyde, following fixation, cells were permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by rabbit IgG APC-conjugated secondary antibody (F0111, R&D Systems).](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Flow-Intracellular-NBP2-46892-img0026.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Effects of PDTC on LC3 on the hippocampus of rats harvested 12 h after CLP. Values of protein data are normalized to actin level and given in relative arbitrary units. LC3-II increased in CLP rats receiving vehicle or PDTC compared with those in sham-operated rats. PDTC + CLP rats showed an increase in LC3-II compared with vehicle-treated rats. Data were expressed as mean +/- SEM, n = 6/group. *P < 0.05 vs sham-operated group. # P < 0.05 vs 12 h or Veh + CLP group. PDTC pyrrolidine dithiocarbamate, LC-3 microtubule-associated protein light chain-3, CLP cecal ligation and puncture. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26067996) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Western-Blot-NBP2-46892-img0038.jpg)
![Immunocytochemistry/Immunofluorescence: LC3B Antibody (1251A) [NBP2-46892] - HeLa cells were treated with Chloroquine for 24 hours prior to fixation, permeabilization and incubation with anti- [Catalog # NBP2-46892] and anti tubulin (NB100-690) antibodies. Image enlargement shows the accumulation of LC3 (green) on autophagosomes in response to Chloroquine treatment. Tubulin staining is shown in red and DNA is counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Immunocytochemistry-Immunofluorescence-NBP2-46892-img0032.jpg)
![Immunohistochemistry-Paraffin: LC3B Antibody (1251A) [NBP2-46892] - IHC (Immunohistochemical) analysis of a formalin fixed and paraffin embedded tissue section of normal mouse brain using rabbit monoclonal LC3B (1251A) antibody [Catalog # NBP2-46892] at 1:100 dilution with HRP-DAB detection. The antibody generated a weak diffused cytoplasmic staining in most of the cells but some cells, especially within empty areas on the section, showed punctate signal also which signifies the presence of autophagy in those areas.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Immunohistochemistry-Paraffin-NBP2-46892-img0033.jpg)
![Flow Cytometry: LC3B Antibody (1251A) [NBP2-46892] - HeLa cells untreated or treated with 50 uM chloroquine for 24h. Image from the Alexa Fluor 405 version of this antibody.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Flow-Cytometry-NBP2-46892-img0037.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Analysis shows lysates of HeLa human cervical epithelial carcinoma cell line untreated (-) or treated (+) with Chloroquine. PVDF membrane was probed with 0.2 ug/mL rabbit anti-LC3B monoclonal Antibody (1251A) (Catalog # NBP2-46892, Novus Biologicals), followed by 1:2000 dilution of goat anti-rabbit IgG secondary antibody. A specific band was detected for LC3B at a molecular weight of approximately 15 kDa in CQ treated NIH-3T3 and PC12 cell lines.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Western-Blot-NBP2-46892-img0009.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Western Blot analysis using HeLa cells treated with (+) or without (-) Chloriquine (CQ). A specific band was detected for LC3B at a molecular weight of approximately 15 kDa.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Western-Blot-NBP2-46892-img0010.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Western Blot image of monoclonal anti-LC3B Antibody (Clone 1251D) [Catalog # NBP2-46892]. HeLa and Neuro2A cells were treated with or without 50 uM chloroquine for 24 hours as indicated. Whole cell protein was then separated on a 4-15% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane for 30 min and blocked in 5% non-fat milk in TBST (Tris-buffered saline, 0.1% Tween 20). The membrane was probed with 2 ug/ml anti-LC3B Antibody in 1% milk, and detected with an anti-rabbit HRP secondary antibody using chemiluminescence. Note the accumulation of LC3B II upon chloroquine treatment. Bands for LC3 were detected at a molecular weight of approximately 15 kDa in treated HeLA cells, and both treated and untreated Neuro2A cells.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Western-Blot-NBP2-46892-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: LC3B Antibody (1251A) [NBP2-46892] - HeLa cells were treated with 50 uM Chloroquine for 24 hour prior to fixation in 10% buffered formalin for 10 min. Cells were permeabilized in 0.1% Triton X-100 and incubated with 20 ug/ml anti- [Catalog # NBP2-46892] and 1:500 anti-tubulin [Catalog # NB100-690] for 1 h at room temperature. LC3B reactivity (green) was detected with ant-rabbit Dylight 488 and tubulin (red) with anti-mouse Dylight 550. Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Immunocytochemistry-Immunofluorescence-NBP2-46892-img0030.jpg)
![Flow (Intracellular): LC3B Antibody (1251A) [NBP2-46892] - HeLa human cervical epithelial carcimoa cell line either treated with 50 uM chloroquine for 24 hours (filled histogram) or untreated (open histogram) was stained with Rabbit anti-Human LC3B Alexa Fluor 647 conjugated monoclonal antiobdy (1251A) [Catalog # NBP2-46892AF647]. To facilitate intracellular staining, cells were fixed and permeabilized with FlowX FoxP3 Fixation and Permeabilization Buffer Kit (FC012-NOV).](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Flow-Intracellular-NBP2-46892-img0025.jpg)
![Immunoprecipitation: LC3B Antibody (1251A) [NBP2-46892] - Western blot analysis of LC3 immunoprecipitation. 10 ug of monoclonal anti-LC3B antibody (clone 1251A) [Catalog # NBP2-46892] was used to immunoprecipitate LC3 from 200 ug of total protein from HeLa cells treated with or without 50 uM chloroquine for 24 h. Antibody-protein was captured by magnetic protein A/G beads, washed and subjected to SDS-PAGE on a 4-15% gel. Protein was transferred to 0.2 um PVDF membrane and probed with 2 ug/ml anti-LC3B (NB100-2220) and detected with an anti-rabbit HRP conjugated secondary antibody using chemiluminescence. The detection of LC3 at a molecular weight of approximately 12 kDa and the antibody heavy chain (Ab Hc) at a molecular weight of approximately 50 kDa is indicated.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Immunoprecipitation-NBP2-46892-img0031.jpg)
![Western Blot: LC3B Antibody (1251A) - BSA Free [NBP2-46892] - Effects of PDTC on LC3 (a), Beclin1 (b), LAMP-1 (c), & Rab7 (d) on the hippocampus of rats harvested 12 h after CLP. Values of protein data are normalized to actin level & given in relative arbitrary units. LC3-II increased while Beclin1, Rab7, & LAMP-1 declined in CLP rats receiving vehicle or PDTC compared with those in sham-operated rats. PDTC + CLP rats showed an increase in LC3-II, Beclin1, Rab7, & LAMP-1 compared with vehicle-treated rats. Data were expressed as mean ± SEM, n = 6/group. *P < 0.05 vs sham-operated group. #P < 0.05 vs 12 h or Veh + CLP group. PDTC pyrrolidine dithiocarbamate, LC-3 microtubule-associated protein light chain-3, CLP cecal ligation & puncture Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-015-0336-2), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-46892_rabbit-monoclonal-lc3b-antibody-1251a-310202415291956.jpg)
![Western Blot: LC3B Antibody (1251A) - BSA Free [NBP2-46892] - a LC3 in brains harvested 3, 6, 12, 24, & 48 h after CLP. b Immunofluorescence for LC3 in neurons after CLP injury. Values of protein data were related to signals obtained from actin protein & given as relative arbitrary units. LC3-II significantly increased in CLP rats at 6, 12, 24, & 48 h after surgery compared with sham-operated rats. Three-color staining for anti-LC3 antibody (green), NeuN (red), & DAPI (blue) showed that a staining pattern changes from largely diffuse to predominantly punctate & cytoplasmic in hippocampal neurons after CLP. Data were expressed as mean ± SEM, n = 6/group. *P < 0.05 vs sham-operated group. LC-3 microtubule-associated protein light chain-3, CLP cecal ligation & puncture, DAPI 4,6-diamidino-2-phenylindole Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-015-0336-2), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-46892_rabbit-monoclonal-lc3b-antibody-1251a-31020241612245.jpg)
![Western Blot: Niemann-Pick type C1 Like-1 Antibody [NB400-128] - Detection of NPC3 in rat small intestine membrane preparations (20 ug). (1) 2 ug/ml and (2) 4 ug/ml. ECL: 30 minute exposure.](http://images.novusbio.com/fullsize/Niemann-Pick-type-C1-Like-1-Antibody-Western-Blot-NB400-128-img0004.jpg "Western Blot: Niemann-Pick type C1 Like-1 Antibody [NB400-128] - Detection of NPC3 in rat small intestine membrane preparations (20 ug). (1) 2 ug/ml and (2) 4 ug/ml. ECL: 30 minute exposure.")
![Immunohistochemistry-Paraffin: Niemann-Pick type C1 Like-1 Antibody [NB400-128] - Staining of human small intestine, enterocytes.](http://images.novusbio.com/fullsize/Niemann-Pick-type-C1-Like-1-Antibody-Immunohistochemistry-Paraffin-NB400-128-img0005.jpg)
![Western Blot: Niemann-Pick type C1 Like-1 Antibody [NB400-128] - Decrease in the biliary cholesterol secretion in L1-Tg mice. Immunoblot detection of hepatic NPC1L1 protein in L1-Tg mice using an anti-NPC1L1 (Niemann-Pick type C1 Like-1) antibody. WT, wild-type. Image collected and cropped by CiteAb from the following publication (//lipidworld.biomedcentral.com/articles/10.1186/s12944-019-1179-0), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Niemann-Pick-type-C1-Like-1-Antibody-Western-Blot-NB400-128-img0006.jpg)
![Western Blot: Niemann-Pick type C1 Like-1 Antibody - BSA Free [NB400-128] - Hepatic NPC1L1‐mediated steatosis in the liver of L1‐Tg mice. A, Hepatic expression of the human NPC1L1 protein in L1‐Tg mice demonstrated by immunoblotting using an anti‐NPC1L1 antibody. alpha ‐Tubulin, a loading control. B, Decrease of biliary cholesterol levels in L1‐Tg mice. Data are expressed as the mean ± SEM n = 6 (WT) & 7 (L1‐Tg). C, Photographic images of the livers of WT & L1‐Tg mice fed a control fat diet (CFD) or a high‐fat diet (HFD) for 2 weeks. The coin diameter was 1 cm. D, Hematoxylin & eosin (H&E) & Oil Red O staining of the livers of WT & L1‐Tg mice fed a HFD for 2 weeks. E & F, Hepatic cholesterol levels (E, left), hepatic triglyceride (TG) levels (E, right), body weight (BW) (F, left), & the ratios of liver weight to BW (L/B ratio) (F, right) in each group of mice fed a CFD or HFD for 2 weeks. Data are expressed as the mean ± SEM n = 11 (WT‐CFD) & 7 (the other groups). Statistical analyses for significant differences were performed using Bartlett's test, followed by a parametric Tukey–Kramer multiple‐comparison test (E, right; F) or a non‐parametric Steel–Dwass test (E, left) (##P < 0.01 vs CFD controls; **P < 0.01 vs. the other groups; *P < 0.05 among two groups; NS, not significantly different among groups) as well as a two‐sided t test (††P < 0.01). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32123832), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-128_rabbit-polyclonal-niemann-pick-type-c1-like-1-antibody-310202416165636.jpg)
![Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Top panel: Analysis of c-Fos expression in HeLa cells using NBP2-50037. Lane 1: HeLa cells were serum-starved for 36 hours. Lane 2: Serum-starved HeLa cells were stimulated with 20% FBS (fetal bovine serum) for 2 hours. NBP2-50037 recognizes bands in the range of 50-65 kDa, which represent multiple forms of c-Fos. Serum starvation attenuates c-Fos expression, while 20% FBS strongly stimulates c-Fos expression. Bottom panel: Blot was stripped and probed with monoclonal antibody against GAPDH (NB300-221) used as loading control.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Western-Blot-NBP2-50037-img0003.jpg "<b>Biological Strategies Validation. </b>Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Top panel: Analysis of c-Fos expression in HeLa cells using NBP2-50037. Lane 1: HeLa cells were serum-starved for 36 hours. Lane 2: Serum-starved HeLa cells were stimulated with 20% FBS (fetal bovine serum) for 2 hours. NBP2-50037 recognizes bands in the range of 50-65 kDa, which represent multiple forms of c-Fos. Serum starvation attenuates c-Fos expression, while 20% FBS strongly stimulates c-Fos expression. Bottom panel: Blot was stripped and probed with monoclonal antibody against GAPDH (NB300-221) used as loading control.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: c-Fos Antibody (2H2) [NBP2-50037] - Section of rat hippocampus stained with mouse monoclonal antibody to c-FOS NBP2-50037 in red and counterstained with rabbit polyclonal antibody to FOX3/NeuN. DAPI reveals nuclei of neurons and glia in blue. The hippocampal neurons stain green for FOX3/NeuN and a few also are expressing c-FOS, and so appear orange. These cells were spontaneously active at the time the animal was sacrificed.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Immunocytochemistry-Immunofluorescence-NBP2-50037-img0006.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and c-Fox knockout (KO) HeLa cell line. PVDF membrane was probed with 1:1000 of Mouse Anti-Human c-Fox Monoclonal Antibody (Catalog # NBP2-50037) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #HAF018). Specific band was detected for c-Fox at approximately 52 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Knockout-Validated-NBP2-50037-img0005.jpg)
![Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Analysis of cell lysates using mouse c-Fos mAb, dilution 1:1,000 (Green), and rabbit GAPDH pAb, dilution 1:20,000 (Red) used as a loading control. [1] protein standard (red), [2] HeLa cells in serum free media. [3] HeLa cells stimulated with 20% fetal bovine serum for 2hrs after 36hrs in serum free media. [4] rat cortical neurons. [5] rat cortical neurons treated with membrane depolarization buffer for 5hrs. Multiple bands at 50-65kDa in stimulated or treated cell lysates correspond to different forms of the c-Fos proten. The single band at 37 kDa represents GAPDH protein.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Western-Blot-NBP2-50037-img0007.jpg)
![Immunohistochemistry: c-Fos Antibody (2H2) [NBP2-50037] - pAb 1:1000 (green), DAPI counterstain (blue) on 30 micron cryosection of mouse spinal cord. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Immunocytochemistry-NBP2-50037-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: c-Fos Antibody (2H2) [NBP2-50037] - Left: NBP2-50037 staining (green) in HeLa cells, which were treated with serum-starvation for 36 hrs, followed by 2 hrs 20% FBS stimulation (bottom), or PBS treatment (top). Green c-Fos staining only localizes in the nuclei of stimulated cells, but not in un-stimulated cells. Cells are counter-stained with chicken pAb against Vimentin (NB300-223, red). Blue shows DAPI staining of nucleus. Middle: Mouse brain section (45 uM; fixed by transcardial perfusion with 4% PFA) labeled with NBP2-50037 using a standard HRP-DAB staining technique. Cells expressing c-Fos show dark color in nucleus. Right: Mouse cortical section labeled with NBP2-50037 (red) and rabbit polyclonal anti-NeuN (NBP1-92716, green) using IF confocal. Neurons positive for c-Fos and RBFOX3/NeuN appear to be yellow. Inset shows an enlarged image of NBP2-50037 staining. Nuclei are labeled with Dapi (blue).](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Immunocytochemistry-Immunofluorescence-NBP2-50037-img0001.jpg)
![Western Blot: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Analysis of P65 using p65 antibody at 2 ug/mL in 30 ug of A) Ramos, B) Daudi, C) HeLa and D) mouse NIH 3T3 cell lysate.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Western-Blot-NB100-56712-img0013.jpg "Western Blot: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Analysis of P65 using p65 antibody at 2 ug/mL in 30 ug of A) Ramos, B) Daudi, C) HeLa and D) mouse NIH 3T3 cell lysate.")
![Simple Western: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Lane view shows a specific band for NFkB p65 in 1.0 mg/mL of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Simple-Western-NB100-56712-img0006.jpg)
![Western Blot: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Lysates of HeLa human cervical epithelial carcinoma cell line and Daudi human Burkitt's lymphoma cell line. PVDF membrane was probed with 1 ug/mL mouse anti-RelA/NFkB p65 monoclonal (NB100-56712, Novus Biologicals), followed by 1:2000 dilution of the appropriate HRP-conjugated secondary antibody, donkey anti-mouse IgG (HAF018).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Western-Blot-NB100-56712-img0016.jpg)
![Immunohistochemistry-Paraffin: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Ovarian cystadenocarcinoma probed with p65 antibody at 5 ug/mL. Human tissue TMA was used for this test. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM sodium citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Immunohistochemistry-Paraffin-NB100-56712-img0009.jpg)
![Flow Cytometry: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Intracellular staining of 293 HEK cells using 0.5 ug of p65 antibody. Green histogram represents the isotype control (p65) antibody. This NFkB p65 antibody was used for this test with an anti-mouse IgG PE conjugated secondary antibody.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Flow-Cytometry-NB100-56712-img0004.jpg)
![Simple Western: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Detection of p65 by Simple Western (JESS) in chemiluminescence in nuclear extract of reconstructed human epidermis lysate (about 600 ug/mL protein concentration).Antibody at 1:20. Simple Western image submitted by a verified customer review.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Simple-Western-NB100-56712-img0017.jpg)
![Western Blot: Calbindin D-28K Antibody [NBP2-50028] - Analysis of different tissue lysates and recombinant protein solutions using chicken pAb to calbindin, NBP2-50028, dilution 1:5,000 in green: [1] protein standard (red), [2] rat cerebellum, [3] pig hippocampus, [4] cow cerebellum, [5] protein standard (red). Next lanes are full length recombinant human proteins, [6] Parvalbumin, [7] Calretinin, [8] Calbindin. Bands at 25kDa in tissue lysates and ~30 kDa in protein solutions correspond to calbindin, the recombinant form being slightly larger due to the presence of a His tag and other vector derived sequence. NBP2-50028 antibody specifically recognizes calbindin protein and does not react with the closely related proteins parvalbumin and calretinin.](http://images.novusbio.com/fullsize/Calbindin-D-28K-Antibody-Western-Blot-NBP2-50028-img0004.jpg "Western Blot: Calbindin D-28K Antibody [NBP2-50028] - Analysis of different tissue lysates and recombinant protein solutions using chicken pAb to calbindin, NBP2-50028, dilution 1:5,000 in green: [1] protein standard (red), [2] rat cerebellum, [3] pig hippocampus, [4] cow cerebellum, [5] protein standard (red). Next lanes are full length recombinant human proteins, [6] Parvalbumin, [7] Calretinin, [8] Calbindin. Bands at 25kDa in tissue lysates and ~30 kDa in protein solutions correspond to calbindin, the recombinant form being slightly larger due to the presence of a His tag and other vector derived sequence. NBP2-50028 antibody specifically recognizes calbindin protein and does not react with the closely related proteins parvalbumin and calretinin.")
![Immunocytochemistry/Immunofluorescence: Calbindin D-28K Antibody [NBP2-50028] - Cultured mouse embryonic kidney stained with Calbindin antibody (1:200) and DAPI. Image from verified customer review.](http://images.novusbio.com/fullsize/Calbindin-D-28K-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-50028-img0005.jpg)
![Immunohistochemistry: Calbindin D-28K Antibody [NBP2-50028] - Representative images of horizontal cells (Calbindin D-28K, cyan) in wild type control and C1q-/- mice at P8, P13, P17, and P23. Horizontal cells in C1q-/- mice fail to remain confined to the OPL, showing an increased number of ectopic neurites (arrowheads) that peak at P13 but remain present as development proceeds. These neurites extend into the outer nuclear layer and grow longer over time. Scale bars = 25 um. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33177995/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Calbindin-D-28K-Antibody-Immunohistochemistry-NBP2-50028-img0007.jpg)
![Western Blot: Calbindin D-28K Antibody [NBP2-50028] - Analysis of rat brain lysate (left), 0.5 ug of His-tagged recombinant proteins (right) were probed with NBP2-50028 at 1:5,000. Lane 1: Parvalbumin, Lane 2: Calretinin, Lane 3: Calbindin.](http://images.novusbio.com/fullsize/Calbindin-D-28K-Antibody-Western-Blot-NBP2-50028-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: Calbindin D-28K Antibody [NBP2-50028] - Adult rat brain cortex (Left) and striatum (Right) sections (45 uM; fixed by transcardial perfusion with 4% paraformaldehyde) were stained with NBP2-50028 (1:1,000, red), and monoclonal mouse anti-RBFOX3/NeuN (NBP1-92693; green). Calbindin labels a subset of sparsely-distributed interneurons (calbindin-positive interneurons) in the cortex (Left), and more densely-distributed neurons in the striatum (Right). Since neurons also express RBFOX3/NeuN, calbindin-positive cells appear to be gold to yellow. Insets are high magnification images of boxed area of each image. Blue is Dapi nucleus staining.](http://images.novusbio.com/fullsize/Calbindin-D-28K-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-50028-img0003.jpg)
![Immunohistochemistry Free-Floating: Calbindin D-28K Antibody [NBP2-50028] - Analysis of rat cerebellum section stained with chicken Calbindin D-28K pAb, dilution 1:2,000 (Green), and costained with rabbit MeCP2 pAb, dilution 1:5,000 (Red). Following transcardial perfusion with 4% paraformaldehyde, brain was post fixed for 24 hours, cut to 45uM, and free-floating sections were stained with above antibodies. Calbindin D-28K, often used as a Purkinje cell marker, is prominently detected in dendrites and perikarya of these cells in the cerebellar molecular layer. The MeCP2 antibody selectively stains nuclei of neuronal cells.](http://images.novusbio.com/fullsize/Calbindin-D-28K-Antibody-Immunohistochemistry-Free-Floating-NBP2-50028-img0006.jpg)
![Immunohistochemistry: Calbindin D-28K Antibody [NBP2-50028] - C1q is expressed in retina microglia during development. (A) qRT-PCR for C1q at P9, P14, & 14 weeks. Values represent the fold mRNA expression level relative to the levels detected in adult animals following normalization to GAPDH. (B) Representative fluorescent in situ hybridization images at P13 of C1q (green) co-stained with either Iba1 (magenta) or calbindin (red) to label microglia & horizontal cells, respectively. C1q colocalizes with microglia but not with horizontal cells in the outer retina at this time (arrowheads). Inset shows C1q expression in Iba1-positive microglia that is absent in calbindin-positive horizontal cells. Scale bars = 25 & 10 μm (inset). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33177995), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-50028_chicken-polyclonal-calbindin-d-28k-antibody-310202415175235.jpg)
![Immunocytochemistry/ Immunofluorescence: Calbindin D-28K Antibody [NBP2-50028] - Myh14 localizes to apical membranes of Atp6v1b1‐positive intercalated cells in the distal tubule. Adult kidney sections were stained for calbindin‐D28K, Atp6v1b1, Aqp2, & Myh14 to identify intercalated cells within the distal & connecting tubule segments as well as to confirm Myh14 localization to the intercalated cell type. Cells with positive staining for Atp6v1b1 (red) can be found in tubule segments positive for calbindin‐D28K only (A–D) as well as in tubules positive for both calbindin‐D28K & Aqp2 (E–H); in both cases Atp6v1b1 staining is observed along the basolateral membrane indicating beta ‐ intercalated cell type (arrowhead, D&H). We also observed Atp6v1b1 staining in majority of the tubules along the apical membrane indicating the alpha ‐ intercalated cell type (arrowhead, I–L). Myh14 localized to the apical membrane of the intercalated cell type in the distal tubule (arrowhead, M–P). Sections were mounted with vectashield containing DAPI to stain the nucleus (blue; D, H, L & P). Scale bar = 10 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29208685), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-50028_chicken-polyclonal-calbindin-d-28k-antibody-310202416121944.jpg)
![Immunohistochemistry: Calbindin D-28K Antibody [NBP2-50028] - Horizontal cells develop normally with the loss of either C3aR or CR3. (A,B) qRT-PCR for complement proteins C3aR & CR3 at P6, P13, & adult in wild type mice. Values represent the fold mRNA expression level relative to the levels detected in control animals following normalization to GAPDH. N = 3 animals. Representative images of horizontal cells (C, anti-calbindin, cyan) & quantifications (D,E) of ectopic horizontal cell neurites in control & C3aR–/– or CR3–/– mice at P13. Horizontal cell neurites in C3aR–/– & CR3–/– mice remain confined to the OPL, showing no increase in the number (D) or length (E) of ectopic neurites (n = 52 sprouts from four control mice; n = 84 sprouts from four C3aR–/– mice; n = 67 sprouts from four CR3–/– mice). Scale bars = 25 μm. Data are represented as the mean ± SEM (D) or as beeswarm SuperPlots (E) in which individual horizontal cell sprout values are presented together with the mean from each animal ± the SEM. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33177995), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-50028_chicken-polyclonal-calbindin-d-28k-antibody-31020241613643.jpg)
![Immunocytochemistry/ Immunofluorescence: Calbindin D-28K Antibody [NBP2-50028] - Myh10 & Myh14 are the NM2 isoforms expressed in the distal & connecting renal tubules. Adult kidney sections were stained for calbindin‐D28K, Aqp2 & one of the NM2 isoforms. Myh9 (A–D) was not expressed in tubules positive for calbindin‐D28K & Aqp2; although adjacent tubules were positive for Myh9 (arrow). Myh10 (E–H) was expressed at low levels at the cell–cell junctions in calbindin‐D28K only positive tubules (white arrowhead), & in tubules positive for both calbindin‐D28K & Aqp2, Myh10 localized to cell–cell junctions, apical, & basolateral membrane (F & H, yellow arrowhead). Myh14 (I–L) was expressed on the apical membrane of calbindin‐D28K & Aqp2 null cells (arrowheads) in the distal tubular segments. Sections were mounted with vectashield containing DAPI to stain the nucleus (blue; D, H, & L). Scale bar = 10 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29208685), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-50028_chicken-polyclonal-calbindin-d-28k-antibody-310202416114730.jpg)
![Western Blot: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Analysis of Caspase-3. Lysates from Jurkat cells (lane 1), normal mammary tissue (lane 2) and surgical specimens from three invasive ductal carcinomas (lanes 3-5) were normalized for total protein content (50 ug/lane) and western blotted with Caspase-3 Antibody - (Pro and Active). The ~32 kDa pro-Caspase-3 protein was detected in all samples. Active/cleaved Caspase-3 was identified in Jurkat and two ductal carcinomas (14-21 kDa large subunit).](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Western-Blot-NB100-56112-img0010.jpg "Western Blot: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Analysis of Caspase-3. Lysates from Jurkat cells (lane 1), normal mammary tissue (lane 2) and surgical specimens from three invasive ductal carcinomas (lanes 3-5) were normalized for total protein content (50 ug/lane) and western blotted with Caspase-3 Antibody - (Pro and Active). The ~32 kDa pro-Caspase-3 protein was detected in all samples. Active/cleaved Caspase-3 was identified in Jurkat and two ductal carcinomas (14-21 kDa large subunit).")
![Immunohistochemistry-Paraffin: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Caspase-3 was detected in immersion fixed paraffin-embedded sections of human bladder tissue 1:300 dilution of rabbit polyclonal Caspase-3 Antibody - (Pro and Active)(NB100-56112), for 1 hour at room temperature followed by anti-rabbit IgG VisUCyte HRP polymer(VC003). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue).](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Immunohistochemistry-Paraffin-NB100-56112-img0011.jpg)
![Simple Western: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Simple Western lane view shows a specific band for Caspase 3 in 0.2 mg/ml of HEK293 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Simple-Western-NB100-56112-img0009.jpg)
![Western Blot: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Effect of acute Cd exposure on BPH1 cell proliferation, Shh signaling activation, and stem cell markers in a time-dependent manner. Cells were incubated with or without 10 uM Cd for the indicated time. Cell lysates were subjected to western blotting using antibodies against p65, Bcl2, BclxL, XIAP, cleaved caspase-3, cleaved PARP, and actin was used as loading control. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41389-020-0202-7), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Western-Blot-NB100-56112-img0012.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Caspase-3 expression in formalin-fixed, paraffin-embedded human reactive lymph node using NB100-56112 (Caspase-3 Antibody - (Pro and Active)) at 1:2000. Staining is seen in the apoptosis-prone germinal center B lymphocytes of follicles.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Immunohistochemistry-Paraffin-NB100-56112-img0008.jpg)
![Immunohistochemistry-Paraffin: Caspase-3 Antibody - (Pro and Active) [NB100-56112] - Analysis of Caspase-3 expression in formalin-fixed, paraffin-embedded human breast ductal carcinoma in situ using this antibody at 1:2000. Staining is seen in the the cancerous ducts, but not in the normal lobulus.](http://images.novusbio.com/fullsize/Caspase-3-Antibody-Pro-and-Active-Immunohistochemistry-Paraffin-NB100-56112-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: CRBN Antibody [NBP1-91810] - Staining of human cell line U-251 MG shows localization to nucleoli. Antibody staining is shown in green.](http://images.novusbio.com/fullsize/CRBN-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-91810-img0027.jpg "Immunocytochemistry/Immunofluorescence: CRBN Antibody [NBP1-91810] - Staining of human cell line U-251 MG shows localization to nucleoli. Antibody staining is shown in green.")
![Western Blot: CRBN Antibody [NBP1-91810] - Analysis in mouse cell line NIH-3T3 and rat cell line NBT-II.](http://images.novusbio.com/fullsize/CRBN-Antibody-Western-Blot-NBP1-91810-img0025.jpg)
![Simple Western: CRBN Antibody [NBP1-91810] - Simple Western lane view shows a specific band for CRBN in 0.2 mg/ml of RT4 (left), U-251MG (right) lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/CRBN-Antibody-Simple-Western-NBP1-91810-img0014.jpg)
![Simple Western: CRBN Antibody [NBP1-91810] - Electropherogram image(s) of corresponding Simple Western lane view. CRBN antibody was used at 1:60 dilution on RT4 and U-251MG lysate(s).](http://images.novusbio.com/fullsize/CRBN-Antibody-Simple-Western-NBP1-91810-img0015.jpg)
![<b>Genetic Strategies Validation. </b>Single Cell Western: CRBN Antibody [NBP1-91810] - CRBN expression after Downregulation by siRNA, dilution 1:500. Single Cell Western Image submitted by verified customer review.](http://images.novusbio.com/fullsize/CRBN-Antibody-Single-Cell-Western-NBP1-91810-img0035.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: CRBN Antibody [NBP1-91810] - Validation of SALL4 asa bona fide IMiD-dependent CRL4CRBN substrate. Parental Kelly cells or two independent pools of CRBN -/- Kelly cells were treated with increasing concentrations of thalidomide. Following 24 h incubation, SALL4, CRBN, and GAPDH protein levels were assessed by western blot analysis. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30067223/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CRBN-Antibody-Western-Blot-NBP1-91810-img0036.jpg)
![Western Blot: SOD1/Cu-Zn SOD Antibody [NBP2-24915] - Bovine ocular fluid. Antibody at 1:1000. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/SOD1-Cu-Zn-SOD-Antibody-Western-Blot-NBP2-24915-img0006.jpg "Western Blot: SOD1/Cu-Zn SOD Antibody [NBP2-24915] - Bovine ocular fluid. Antibody at 1:1000. Western blot image submitted by a verified customer review.")
![Immunohistochemistry-Paraffin: SOD1/Cu-Zn SOD Antibody [NBP2-24915] - Analysis of Superoxide Dismutase 1 in FFPE human liver tissue using an isotype control (top) and NBP2-24915 (bottom) at 5 ug/ml.](http://images.novusbio.com/fullsize/SOD1-Cu-Zn-SOD-Antibody-Immunohistochemistry-Paraffin-NBP2-24915-img0003.jpg)
![Western Blot: SOD1/Cu-Zn SOD Antibody [NBP2-24915] - Analysis of SOD in liver lysate of 1) human, 2) mouse, and 3) rat using this antibody. 025 ug/ml.](http://images.novusbio.com/fullsize/SOD1-Cu-Zn-SOD-Antibody-Western-Blot-NBP2-24915-img0004.jpg)
![Western Blot: SOD1/Cu-Zn SOD Antibody [NBP2-24915] - Human ocular fluid. Antibody at 1:1000. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/SOD1-Cu-Zn-SOD-Antibody-Western-Blot-NBP2-24915-img0005.jpg)